Stay updated on Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial

Sign up to get notified when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The footer’s displayed site revision changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T15:37:13.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T15:36:48.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the usual study record content. The standard study details and navigation are not accessible on this page.
    Difference
    17%
    Check dated 2026-09-19T19:36:37.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    The study page's revision tag was updated from v3.6.5 to v3.6.6, indicating a minor metadata update to the record. No substantive study content appears to be changed.
    Difference
    0.1%
    Check dated 2026-08-29T20:17:42.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    The study page now includes expanded MeSH terms and related metadata. This enhances indexing and cross-referencing without changing enrollment, design, or results.
    Difference
    51%
    Check dated 2026-08-16T01:16:29.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page revision tag changed from v3.6.4 to v3.6.5, signaling a newer version of the ClinicalTrials.gov entry. This reflects an update to the page metadata or minor content refinements without altering the study's data or eligibility details.
    Difference
    0.1%
    Check dated 2026-08-08T23:23:15.000Z thumbnail image

Stay in the know with updates to Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.